CF
DRNA

Centaurus Financial’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Centaurus Financial’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-300
Closed -$4K – 2250
2018
Q2 		$4K Buy
+300
New +$3.77K ﹤0.01% 1901

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Centaurus Financial's DRNA Position: Q3 2018 in Review

Centaurus Financial sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2018, closing a stake of 300 shares — an estimated $4K sold.

Centaurus Financial first reported a position in DRNA in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 95 funds tracked by Wall St. Rank hold DRNA as of Q3 2018.

  • Centaurus Financial reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 300 Dicerna Pharmaceuticals, Inc. shares in Q3 2018, an estimated $4K.
  • Centaurus Financial first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Dicerna Pharmaceuticals, Inc. position peaked at $4K in Q2 2018.
  • 95 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.